Literature DB >> 11451951

Human acid ceramidase: processing, glycosylation, and lysosomal targeting.

K Ferlinz1, G Kopal, K Bernardo, T Linke, J Bar, B Breiden, U Neumann, F Lang, E H Schuchman, K Sandhoff.   

Abstract

The biosynthesis of human acid ceramidase (hAC) starts with the expression of a single precursor polypeptide of approximately 53-55 kDa, which is subsequently processed to the mature, heterodimeric enzyme (40 + 13 kDa) in the endosomes/lysosomes. Secretion of hAC by either fibroblasts or acid ceramidase cDNA-transfected COS cells is extraordinarily low. Both lysosomal targeting and endocytosis critically depend on a functional mannose 6-phosphate receptor as judged by the following criteria: (i) hAC-precursor secretion by NH(4)Cl-treated fibroblasts and I-cell disease fibroblasts, (ii) inhibition of the formation of mature heterodimeric hAC in NH(4)Cl-treated fibroblasts or in I-cell disease fibroblasts, and (iii) blocked endocytosis of hAC precursor by mannose 6-phosphate receptor-deficient fibroblasts or the addition of mannose 6-phosphate. The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was determined by site-directed mutagenesis. Five glycosylation sites (sites 1-5 from the N terminus) are used. The elimination of sites 2, 4, and 6 has no influence on lysosomal processing or enzymatic activity of recombinant ceramidase. The removal of sites 1, 3, and 5 inhibits the formation of the heterodimeric enzyme form. None of the mutant ceramidases gave rise to an increased rate of secretion, suggesting that lysosomal targeting does not depend on one single carbohydrate chain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451951     DOI: 10.1074/jbc.M103066200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Shaping the landscape: metabolic regulation of S1P gradients.

Authors:  Ana Olivera; Maria Laura Allende; Richard L Proia
Journal:  Biochim Biophys Acta       Date:  2012-06-23

2.  In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.

Authors:  Shobha Ramsubir; Takahiro Nonaka; Carmen Bedia Girbés; Stéphane Carpentier; Thierry Levade; Jeffrey A Medin
Journal:  Mol Genet Metab       Date:  2008-09-20       Impact factor: 4.797

3.  Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function.

Authors:  Iyad Sultan; Can E Senkal; Suriyan Ponnusamy; Jacek Bielawski; Zdzislaw Szulc; Alicja Bielawska; Yusuf A Hannun; Besim Ogretmen
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

4.  Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression.

Authors:  Natasha C Lucki; Sibali Bandyopadhyay; Elaine Wang; Alfred H Merrill; Marion B Sewer
Journal:  Mol Endocrinol       Date:  2012-01-19

Review 5.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization.

Authors:  Efrat Eliyahu; Nataly Shtraizent; Kurt Martinuzzi; Jason Barritt; Xingxuan He; Hong Wei; Sanjeev Chaubal; Alan B Copperman; Edward H Schuchman
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

7.  Autoproteolytic cleavage and activation of human acid ceramidase.

Authors:  Nataly Shtraizent; Efrat Eliyahu; Jae-Ho Park; Xingxuan He; Ruth Shalgi; Edward H Schuchman
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

Review 8.  An introduction to sphingolipid metabolism and analysis by new technologies.

Authors:  Yanfeng Chen; Ying Liu; M Cameron Sullards; Alfred H Merrill
Journal:  Neuromolecular Med       Date:  2010-08-03       Impact factor: 3.843

9.  Potent inhibition of Acid ceramidase by novel B-13 analogues.

Authors:  Denny Proksch; Jan Jasper Klein; Christoph Arenz
Journal:  J Lipids       Date:  2010-12-09

Review 10.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.